Research Article
Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry
Table 4
Bivariate analysis grouped by two main advanced interventions (catheter-directed interventions versus systemic thrombolysis)
| | Catheter-directed intervention (N = 145) | Systemic thrombolysis (N = 154) | Overall (N = 299) | P value |
| Age | Mean (SD), years | 55.8 (15.0) | 55.4 (15.1) | 55.6 (15.0) | 0.816 |
| Race | White | 79 (54.5%) | 90 (58.4%) | 169 (56.5%) | 0.714 | Black | 62 (42.8%) | 61 (39.6%) | 123 (41.1%) | | American-Indian/Alaskan | 1 (0.7%) | 0 (0%) | 1 (0.3%) | | Asian | 1 (0.7%) | 0 (0%) | 1 (0.3%) | | Unknown | 2 (1.4%) | 3 (1.9%) | 5 (1.7%) | |
| Gender | Female | 71 (49.0%) | 77 (50.0%) | 148 (49.5%) | 0.908 | Male | 74 (51.0%) | 77 (50.0%) | 151 (50.5%) | |
| Ethnicity | Hispanic | 2 (1.4%) | 4 (2.6%) | 6 (2.0%) | 0.376 | Non-Hispanic | 135 (93.1%) | 146 (94.8%) | 281 (94.0%) | | Unknown | 8 (5.5%) | 4 (2.6%) | 12 (4.0%) | |
| Advanced treatment timing | Yes (delayed >12 hrs later) | 64 (44.1%) | 18 (11.7%) | 82 (27.4%) | <0.001 | Yes (within 12 hrs) | 81 (55.9%) | 135 (87.7%) | 216 (72.2%) | |
| Major bleeding | No | 126 (86.9%) | 121 (78.6%) | 247 (82.6%) | 0.0673 | Yes | 19 (13.1%) | 33 (21.4%) | 52 (17.4%) | |
| Clinical deterioration | CD | 18 (12.4%) | 72 (46.8%) | 90 (30.1%) | <0.001 | No CD | 127 (87.6%) | 82 (53.2%) | 209 (69.9%) | |
| Death | No | 139 (95.9%) | 124 (80.5%) | 263 (88.0%) | <0.001 | Yes | 6 (4.1%) | 30 (19.5%) | 36 (12.0%) | |
| PE severity at presentation | High risk | 9 (6.2%) | 57 (37.0%) | 66 (22.1%) | <0.001 | Intermediate-high risk | 81 (55.9%) | 76 (49.4%) | 157 (52.5%) | | Intermediate-low risk | 55 (37.9%) | 20 (13.0%) | 75 (25.1%) | | Low risk | 0 (0%) | 1 (0.6%) | 1 (0.3%) | |
| Bleeding risk | High | 14 (9.7%) | 14 (9.1%) | 28 (9.4%) | 0.904 | Moderate | 60 (41.4%) | 68 (44.2%) | 128 (42.8%) | | Low | 71 (49.0%) | 72 (46.8%) | 143 (47.8%) | |
| PE severity/bleeding risk profile | High-risk PE/high bleeding risk | 2 (1.4%) | 8 (5.2%) | 10 (3.3%) | <0.001 | High-risk PE/moderate bleeding risk | 3 (2.1%) | 27 (17.5%) | 30 (10.0%) | | High-risk PE/low bleeding risk | 4 (2.8%) | 22 (14.3%) | 26 (8.7%) | | Intermediate-high-risk PE/high bleeding risk | 11 (7.6%) | 5 (3.2%) | 16 (5.4%) | | Intermediate-high PE/moderate bleeding risk | 35 (24.1%) | 34 (22.1%) | 69 (23.1%) | | Intermediate-high PE/low bleeding risk | 35 (24.1%) | 37 (24.0%) | 72 (24.1%) | | Intermediate-low PE/high bleeding risk | 1 (0.7%) | 1 (0.6%) | 2 (0.7%) | | Intermediate-low PE/moderate bleeding risk | 22 (15.2%) | 6 (3.9%) | 28 (9.4%) | | Intermediate-low PE/low bleeding risk | 32 (22.1%) | 14 (9.1%) | 46 (15.4%) | |
| Clinical site | AH Carolinas Medical Center | 8 (5.5%) | 89 (57.8%) | 97 (32.4%) | <0.001 | AH Cabarrus | 34 (23.4%) | 18 (11.7%) | 52 (17.4%) | | AH Mercy | 1 (0.7%) | 1 (0.6%) | 2 (0.7%) | | AH Pineville | 68 (46.9%) | 19 (12.3%) | 87 (29.1%) | | AH Union | 3 (2.1%) | 7 (4.5%) | 10 (3.3%) | | AH University City | 28 (19.3%) | 3 (1.9%) | 31 (10.4%) | | CHS Blue Ridge/Morganton | 1 (0.7%) | 2 (1.3%) | 3 (1.0%) | | AH Cleveland | 0 (0%) | 9 (5.8%) | 9 (3.0%) | | AH Kings Mountain | 0 (0%) | 1 (0.6%) | 1 (0.3%) | | AH Stanly | 0 (0%) | 1 (0.6%) | 1 (0.3%) | | Missing | 2 (1.4%) | 4 (2.6%) | 6 (2.0%) | |
|
|